In general, there have been no differences in response to therapy and survival between IDH1/2-mutated versus IDH1/2-wild type AML patients (Abbas et al., 2010; Chou et al., 2010; Thol et al., 2010a; Wagner et al., 2010; Marcucci et al., 2011). This evidence concerns the gene IDH1 and acute myeloid leukemia.